Corcept Faces Shareholder Scrutiny After $3.6 Billion Market Value Loss
Corcept Therapeutics (NASDAQ:CORT) is in the spotlight after a tumultuous start to 2026. The company is now the subject of a shareholder rights investigation by Hagens Berman, following the FDA’s rejection of its highly anticipated drug, relacorilant—a treatment for hypercortisolism (Cushing’s syndrome). The fallout has been swift: CORT shares plunged 50% in a single trading session on December 31, 2025, erasing over $3.6 billion in market capitalization.
FDA Rejection Triggers Major Selloff: $35 Drop in a Day
Corcept had spent months assuring investors about relacorilant's efficacy, safety, and near-term commercial prospects, with public statements highlighting clinical improvements and management projections of growing the company's hypercortisolism business to $5 billion in annual revenue within five years. Those ambitions came to a screeching halt when the FDA responded with a Complete Response Letter, signaling it was unconvinced by the current evidence. Shares cratered as investors processed the abrupt reversal in outlook.
| Date | Event | Impact |
|---|---|---|
| Dec 31, 2025 | FDA rejects relacorilant (CRL issued) | Share price falls over $35 (-50%) |
| Jan 21, 2026 | Investigation announced by Hagens Berman | Shareholder rights litigation launched |
Investigators Question Prior Promises of Efficacy and Growth
The investigation is focused on whether Corcept may have misled investors by overstating relacorilant’s clinical performance and the wider financial prospects for the hypercortisolism business. Hagens Berman notes that Corcept previously assured investors not only of clinically meaningful improvements in trial patients, but also of a confident path to FDA approval and rapid, multi-billion dollar revenue growth. The FDA’s need for further evidence of the drug’s effectiveness calls these statements into question.
Market and Investor Reaction: Where Does CORT Stand Now?
Trading at $42.29 as of midday on January 21, 2026, CORT remains well below its late-2025 highs, with investors reassessing both the timeline and likelihood of relacorilant’s eventual approval. The abrupt price reset reflects doubts about prior company projections and the uncertainty that now clouds Corcept's core growth story.
| Metric | Value |
|---|---|
| Current Share Price | $42.29 |
| Market Cap Lost (Dec 31, 2025) | $3.60 billion |
| Price Change Since Dec 31, 2025 | -50% |
What Investors Should Watch Next
For investors, the key questions now revolve around the scope of the investigation, potential for class action, and whether Corcept can provide the additional evidence the FDA is demanding for relacorilant. While HCPLive reported that relacorilant-treated patients had an 83% lower chance of loss of blood pressure control compared to placebo, this outcome was not sufficient for immediate approval—raising the bar for what evidence the company must produce next.
As the story develops, CORT shareholders and potential investors will want to closely watch the firm’s regulatory path forward and disclosure of any new clinical data. The resolution of the investigation, and Corcept’s ability to address FDA concerns, could determine whether the stock eventually reverses course or remains under pressure. Until then, caution and scrutiny are likely to define the CORT narrative.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI